The product information states that:
Premedication for daratumumab should consist of an oral antipyretic, oral or intravenous antihistamine and intravenous corticosteroid. Following the second infusion the dose of corticosteroid may be reduced and given intravenously or orally.
- Monotherapy: an oral corticosteroid should be given for 2 days after all daratumumab infusions (beginning the day after the infusion).
- Combination therapy: consider administrating oral corticosteroid the day after daratumumab infusion. However if a background regimen-specific corticosteroid is administered the day after daratumumab infusion, additional post-infusion may not be needed.
Additionally, for patients with a history of chronic obstructive pulmonary disease, consider the use of post-infusion medications including short and long acting bronchodilators, and inhaled corticosteroids. Following the first four infusions, if the patient experiences no major IRRs, these inhaled post-infusion medications may be discontinued at the discretion of the physician.
A suggested default premedication and post medication has been added to the treatment schedule and may be substituted to reflect institutional policy.